This is a working overview of LY3437943, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-19 and is reviewed periodically as new material appears.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
=== Human resources === In 2013, Merck KGaA reported problems with recruiting and retaining qualified employees: "Sourcing, recruiting and retaining specialists and talent at Merck are among the company's top priorities. Nevertheless, employee-related risks that affect business activities are likely, even though their impact is difficult to assess. Merck rates this as a medium risk." Merck KGaA further reported with respect to its pharma division, Merck Serono: "Over 80% of the Merck Serono senior management positions [have been] replaced since 2011 [as of September 2014]."
Chiang's general He Yingqin then proposed building a highway from Kangding to Xining through Yushu, but Liu once again blocked Nationalist attempts to introduce its soldiers in Xikang. Kim Hee-shin argues that Liu, in his dealings with various political factions, was mainly driven by political survival, with ideology playing little to no role in his considerations. This meant that although Xikang cooperated with the central government, he maintained ties with anti-Chiang factions and refused to let Nationalist garrisons into his province. An attempt by the Nationalist official H. H. Kung to more closely oversee Xikang's affairs in 1939 ended in failure after the representative he sent, Peter Goullart, was placed under house arrest by Liu's forces. To prevent the CC Clique from taking control of his province, Liu used his position as head of the provincial government to block their influence.
In 2011, the FDA approved a phase I trial that used telemonitoring, also known as remote patient monitoring, to collect biometric data in patients' homes and transmit it electronically to the trial database. This technology provides many more data points and is far more convenient for patients, because they have fewer visits to trial sites. As noted below, decentralized clinical trials are those that do not require patients' physical presence at a site, and instead rely largely on digital health data collection, digital informed consent processes, and so on.
=== Sequence similarity === EC categories do not reflect sequence similarity. For instance, two ligases of the same EC number that catalyze exactly the same reaction can have completely different sequences. Independent of their function, enzymes, like any other proteins, have been classified by their sequence similarity into numerous families. These families have been documented in dozens of different protein and protein family databases such as Pfam.
Sources: en.wikipedia.org
The historicity of the United Monarchy is heavily debated among archaeologists and biblical scholars: biblical maximalists and centrists (Kenneth Kitchen, William G. Dever, Amihai Mazar, Baruch Halpern and others) argue that the biblical account is more or less accurate, while biblical minimalists (Israel Finkelstein, Ze'ev Herzog, Thomas L. Thompson and others) argue that Israel and Judah never split from a singular state. The debate has not been resolved, but recent archaeological discoveries by Eilat Mazar and Yosef Garfinkel show some support for the existence of the United Monarchy. From 850 BCE onwards, a series of inscriptions mention the "House of David". They came from Israel's neighbours.
=== Phase II === Study 980231 (Randomized, double-blind, placebo-controlled). Three dose regimens were included: "pre-post", "pre", and placebo Palifermin administration (60 micrograms/kg) by IV for three consecutive days before chemotherapy and after autologous peripheral blood progenitor cell (PBPC). Efficacy was demonstrated in the drug versus the placebo.
===== Drug trafficking ===== 17 November 2013: Yong Vui Kong, a Malaysian found guilty of drug trafficking in 2007 and sentenced to death in 2008. He lost multiple appeals against his sentence to the Court of Appeal and President of Singapore. However, when changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment and 15 strokes of the cane. Yong was the first drug convict on death row to be spared the gallows since the 2013 law reforms. 6 January 2014: Subashkaran Pragasam, a Singaporean found guilty of trafficking heroin in 2008 and sentenced to death in 2012. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. 3 March 2014: Dinesh Pillai Reja Retnam, a Malaysian found guilty of trafficking heroin in 2009 and sentenced to death in 2011. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment on the grounds of diminished responsibility due to him suffering from depression when he committed the crime. 27 May 2014: Yip Mun Hei, a Singaporean convicted of trafficking heroin in 2008 and sentenced to death in 2009. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. He had an accomplice Leong Soy Yip (also sentenced to death) whose fate remains unknown.
Using cells in culture Pre-treating cells in a hypotonic solution, which swells them and spreads the chromosomes Arresting mitosis in metaphase by a solution of colchicine Squashing the preparation on the slide forcing the chromosomes into a single plane Cutting up a photomicrograph and arranging the result into an indisputable karyogram. It took until 1956 for it to be generally accepted that the karyotype of man included only 46 chromosomes. The great apes have 48 chromosomes. Human chromosome 2 was formed by a merger of ancestral chromosomes, reducing the number.
== Potential issues == While there is good evidence for the efficacy of opioid rotation as a treatment approach in general, there is less evidence for what particular opioid analgesics are most suitable, and in practice the choice of opioid drugs used depends on many factors such as patient characteristics, prescriber preferences and safety. One issue with opioid rotation is that an opioid therapy failure poorly predicts whether other opioids would be effective. In certain situations, multiple switches may be required before pain therapy is optimized. In addition, recent studies explore which opioid drugs are most effective in implementing in an opioid rotation, but have so far found no difference in efficacy between opioid drugs like methadone and fentanyl in cancer patients. Diversion of prescribed opioid drugs for illicit recreational use is also a particular concern in this field, as the drugs which are most effective for relieving suffering in palliative care also tend to be those most sought after by drug abusers. The choice of what opioid drug to use in which patient thus tends to be a balance between many different factors that must be considered, and the need for opioid rotation in chronic pain patients makes it advantageous for a wide range of different opioid drugs to be available, even though they may be broadly equivalent in action when used in shorter term treatment. Additionally, newer studies may explore which patient populations can benefit the most from opioid rotation and which populations can have their pain managed by other means.
Sources: en.wikipedia.org
==== Concerns ==== An analysis conducted in late 2020 of premarket vaccine purchase commitments indicated that wealthy countries may receive their vaccines in 2020–21 while developing countries may be excluded from vaccinations until 2023–24. Data from April 2021 comports with this expectation since 25% of the population in high income countries have been vaccinated compared to only 0.2% in low income countries. The head of the World Health Organization said on 4 August 2021 that rich countries had administered about 100 doses per 100 people while poor countries had administered only about 1.5 doses for every 100 people, and therefore, in his estimation, it was important to prioritize vaccination in poor countries before offering booster vaccines in rich countries. The WHO Director General Tedros Adhanom Ghedreyesus raised concerns about rich countries hoarding vaccines at the expense of citizens in poorer nations who wait for vaccines to either become available or are donated. The WHO Regional Office of Africa highlighted vaccine discard in African countries, after Nigeria destroyed about 1 million donated doses of AstraZeneca vaccine after being donated with only a few weeks till expiration. Other countries such as Malawi, and South Sudan have either destroyed expired or close to expiring vaccines or paused donated shipments due to expiration concerns.
=== Re-creation mount === Re-creation mounts are accurate life-size representations of either extant or extinct species that are created using materials not found on the animal being rendered. They utilize the fur, feathers, and skin of other species of animals. According to the National Taxidermy Association: "Re-creations, for the purpose of this [competition] category, are defined as renderings which include no natural parts of the animal portrayed. A re-creation may include original carvings and sculptures. A re-creation may use natural parts, provided the parts are not from the species being portrayed. For instance, a re-creation eagle could be constructed using turkey feathers, or a cow hide could be used to simulate African game". A famous example of a re-creation mount is a giant panda created by taxidermist Ken Walker that he constructed out of dyed and bleached black bear fur.
Intending to wrest back the initiative, sever UNITA's logistics lifelines to South West Africa and Zaire, and forestall any future insurgent offensives, FAPLA launched Operation Saluting October in mid-1987. The impetus for Saluting October likely originated with the Soviet military mission, which pressed the idea of a major conventional thrust to destroy UNITA's southeastern front as early as 1983. It had received a new commander that year, Lieutenant General Pyotr Gusev, former deputy commander of the Carpathian Military District. In light of the war's length, its cost, the rising death toll, and looming cuts in the Soviet military expenditure which would limit future efforts to support FAPLA's war effort, Gusev wanted a decisive multi-divisional offensive to crush UNITA once and for all. Operation Saluting October was a two-pronged offensive aimed at retaking three major settlements from UNITA, Cangamba, Cassamba, and Mavinga. The FAPLA command staff intended the attack on Cangamba and Cassamba as a feint, hoping to draw UNITA forces there and away from Mavinga. Once Mavinga was in government hands, FAPLA could expel the remaining insurgents from Moxico Province and pave the way for a final assault on Savimbi's headquarters at Jamba. Between 4 and 9 Soviet advisers were to be attached on the battalion level, albeit with strict orders not to participate in the fighting and withdraw from the front as necessary to avoid contact with UNITA. They were accompanied by a small number of Cuban advisers and East German technical personnel serving in a variety of support roles.
=== Oral vaccines === Notable developments in vaccine delivery technologies have included oral vaccines. Early attempts to apply oral vaccines showed varying degrees of promise, beginning early in the 20th century, at a time when the very possibility of an effective oral antibacterial vaccine was controversial. By the 1930s there was increasing interest in the prophylactic value of an oral typhoid fever vaccine for example. An oral polio vaccine turned out to be effective when vaccinations were administered by volunteer staff without formal training; the results also demonstrated increased ease and efficiency of administering the vaccines. Effective oral vaccines have many advantages; for example, there is no risk of blood contamination. Vaccines intended for oral administration need not be liquid, and as solids, they commonly are more stable and less prone to damage or spoilage by freezing in transport and storage. Such stability reduces the need for a "cold chain": the resources required to keep vaccines within a restricted temperature range from the manufacturing stage to the point of administration, which, in turn, may decrease costs of vaccines.
. The sign of the parameter will depend on the sign of the constant potential at each step, and the appropriate matrix will depend on the sign of the parameter. Because a digital waveform may be approximated as existing in only high and low states (potential sign), the stability of ions, as demonstrated by Brabeck, may be determined in as few as two or three constant potential steps. In the simple but frequent case that a full cycle of a digital waveform can be represented by two constant potential steps, the matrix representing the first potential step would be multiplied onto the matrix representing the second potential step. In the general case, the final matrix of a waveform cycle defined by n constant potential steps is:
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.